Glaxosmithkline Pharmaceuticals Reports Decline in Key Financial Metrics for June 2025

Glaxosmithkline Pharmaceuticals has recently reported its financial results for the quarter ending June 2025, revealing notable trends in its performance. The company has experienced a decline in its financial metrics, with net sales recorded at Rs 805.17 crore, reflecting a significant shift compared to the average of the previous four quarters, which stood at Rs 937.30 crore. This trend indicates challenges in maintaining sales momentum. Profit Before Tax (PBT) also showed a downward adjustment, reported at Rs 235.26 crore, which is lower than the average PBT of Rs 277.32 crore from the last four quarters. Similarly, Profit After Tax (PAT) decreased to Rs 205.01 crore, down from an average of Rs 231.03 crore in the previous periods. Additionally, the Debtors Turnover Ratio has reached its lowest point at 12.82 times, suggesting a slowdown in the company's ability to settle its debts. While non-operating income has seen an uptick, reaching Rs 43.72 crore, this increase may not be indicative of sustainable growth. Overall, Glaxosmithkline Pharmaceuticals has undergone evaluation changes in its financial standing, reflecting the challenges faced in the current market environment. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.